Extrait

This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.

Critère d'inclusion

• Early Stage Parkinson Disease

Pays

• Australia
• Czech Republic
• Estonia
• France
• Germany
• India
• Italy
• Lithuania
• Malaysia
• Netherlands
• Poland
• Portugal
• South Africa
• Spain
• Taiwan, Province of China
• Thailand
• United Kingdom
• United States

Liens

• ictrp
• nct